MSF frequently publishes updates, press releases, and other forms of communication about its work in roughly 70 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

A mobile team of MSF medics is traveling to remote villages in the unstable southeast of Central African Republic to find and treat people suffering from a neglected disease.

More >

Sleeping sickness is a fatal and much neglected disease that plagues parts of Africa.

More >

Decades of conflict and a lack of government investment have made it difficult for people in DRC to access even the most basic health care. 

More >

Geneva/Kampala, September 22, 2009 - NECT (Nifurtimox-Eflornithine Combination Therapy), the first new treatment in 25 years against Human African trypanosomiasis (HAT) or sleeping sickness, is now available. Endemic countries have now begun the process of ordering the new combination treatment and kits through the World Health Organization (WHO). Developed by DNDi and its partners, NECT cuts the cost of treatment by half and significantly reduces the burden on health workers. The announcement was made today at the International Scientific Council for Trypanosomiasi Research and Control (ISCTRC), in Kampala, Uganda.

More >

Half a year after Doctors Without Borders/Médecins Sans Frontières (MSF) were forced to abandon its project in the northeastern Democratic Republic of Congo (DRC) due to the security situation, it is still not safe to return. Meanwhile, infection levels of sleeping sickness, which was a main focus of MSF’s activities in the area, are on the rise and many vulnerable people are at risk to the fatal disease.

More >

Geneva/New York, May 15, 2009 – A new treatment option for sleeping sickness, a fatal disease that threatens 60 million people across sub-Saharan Africa, has been added to the Essential Medicines List (EML) of the World Health Organization (WHO). The inclusion of NECT (Nifurtimox-Eflornithine Combination Therapy) is based on an application submitted by the non-profit Drugs for Neglected Diseases initiative (DNDi), supported by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF), and Epicentre, MSF’s epidemiological research center.

More >

Geneva/New York, February 23, 2009 — MSF and the Drugs for Neglected Diseases initiative (DNDi) called today for more sustainable funding for research and development (R&D) to tackle deadly, yet neglected diseases, such as sleeping sickness, visceral leishmaniasis, and Chagas disease, that affect millions of people around the world.

More >

New Orleans, Paris, Geneva; December 9, 2008 – Positive results from a pivotal, multi-center, multi-country Phase III trial investigating an improved treatment for the advanced stage of sleeping sickness were presented yesterday at the 57th Annual Meeting of the American Society of Tropical Medicine & Hygiene held in New Orleans, Louisiana, USA. This trial shows conclusively that NECT is a safe, effective, and practical treatment.

More >

Atlanta, November 15, 2006 — Preliminary results from a study conducted by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) show that significantly shorter and simplified treatment of African sleeping sickness (human African trypanosomiasis — HAT) could be possible in the near future. Announcing the study today at the 55th annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta, the organization stressed that measures must be undertaken to ensure that this treatment can be used as soon as possible at country level, and that older, toxic treatments are phased out."

More >

Pages